Dow AgroSciences and Cheminova Agree To Form Joint Venture
New Company will Manufacture Advanced Pyrethroid
INDIANAPOLIS – December 12, 2000 — Dow AgroSciences LLC, Indianapolis, Ind., U.S.A., and Cheminova A/S, Lemvig, Denmark, have agreed to form a 50:50 joint venture to register and market a premium pyrethroid insecticide. The new Zurich-based company, Pytech Chemicals GmbH, will develop products with superior efficacy at lower application rates than any pyrethroid insecticide available today. The new insecticide will be introduced initially in agricultural row crops and will target chewing and sucking insects, a market that accounts for US $1.5 billion worldwide sales of pyrethroids each year.
Products developed by Pytech Chemicals are expected to be introduced in the U.S. in 2003, with worldwide distribution occurring in 2004. Terms of the joint venture were not disclosed.
"Pytech Chemicals provides significant strategic and commercial value by introducing a product that is substantially more active than other pyrethroid insecticides," explained Stan Howell, Global Leader for Insect and Disease Management at Dow AgroSciences. "By adding a world-class pyrethroid to our stable of leading insecticides, chlorpyrifos and spinosad, Dow AgroSciences will be able to offer customers an expanded portfolio of products with different modes of action."
BjØrn Albinus, managing director, Cheminova A/S, said the joint venture will facilitate expansion of Cheminova's product offering and will demonstrate its leadership in the production of plant protection chemistry.
"Cheminova A/S is committed to producing and marketing internationally a wide range of plant protection products by in-house process development, registration and the development of formulations," he says. "Pytech Chemicals is a hallmark of that vision.
"Pyrethroid manufacturers have been moving to resolved isomers as a way to increase efficacy and lower rates of application. We've done the industry one better by producing the most active isomer directly by stereoselective process," Albinus explained. "This single isomer pyrethroid is a true advancement, delivering greater efficacy at lower use-rates."
Other news from the department
